133 related articles for article (PubMed ID: 25399713)
1. Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing.
Janssens AC; Deverka PA
Clin Pharmacol Ther; 2014 Dec; 96(6):652-4. PubMed ID: 25399713
[No Abstract] [Full Text] [Related]
2. Practical considerations for pharmacogenetic testing.
Wedlund PJ
MLO Med Lab Obs; 2001 Sep; 33(9):16-21, 23; quiz 24-5. PubMed ID: 11569125
[No Abstract] [Full Text] [Related]
3. Pharmacogenetics and cost-effectiveness analysis: a two-way street.
Chalkidou K; Rawlins M
Drug Discov Today; 2011 Oct; 16(19-20):873-7. PubMed ID: 21903176
[TBL] [Abstract][Full Text] [Related]
4. Overview of the pharmacoeconomics of pharmacogenetics.
Dervieux T; Bala MV
Pharmacogenomics; 2006 Dec; 7(8):1175-84. PubMed ID: 17184205
[TBL] [Abstract][Full Text] [Related]
5. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.
Serretti A; Olgiati P; Bajo E; Bigelli M; De Ronchi D
World J Biol Psychiatry; 2011 Oct; 12(7):501-15. PubMed ID: 21595526
[TBL] [Abstract][Full Text] [Related]
6. Estimating the Danish populations' preferences for pharmacogenetic testing using a discrete choice experiment. The case of treating depression.
Herbild L; Bech M; Gyrd-Hansen D
Value Health; 2009 Jun; 12(4):560-7. PubMed ID: 18980634
[TBL] [Abstract][Full Text] [Related]
7. Testing HLA-B*15:02: Is it worth it?
Marson A; Guerrini R
Neurology; 2016 Mar; 86(12):1080-1. PubMed ID: 26888996
[No Abstract] [Full Text] [Related]
8. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
[TBL] [Abstract][Full Text] [Related]
9. Scanning the human genome and the horizon: the potential and pitfalls of pharmacogenetics and stratified medicine.
Jennings BA; Shakespeare T; Loke YK
Br J Gen Pract; 2015 Jun; 65(635):284-5. PubMed ID: 26009508
[No Abstract] [Full Text] [Related]
10. Pharmacogenetic testing in psychiatry: a review of features and clinical realities.
de Leon J; Arranz MJ; Ruaño G
Clin Lab Med; 2008 Dec; 28(4):599-617. PubMed ID: 19059065
[TBL] [Abstract][Full Text] [Related]
11. The value of routine pharmacogenomic screening-Are we there yet? A perspective on the costs and benefits of routine screening-shouldn't everyone have this done?
Veenstra DL
Clin Pharmacol Ther; 2016 Feb; 99(2):164-6. PubMed ID: 26565561
[TBL] [Abstract][Full Text] [Related]
12. Context, ethics and pharmacogenetics.
Hedgecoe AM
Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):566-82. PubMed ID: 16980195
[TBL] [Abstract][Full Text] [Related]
13. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues.
Gillis NK; Innocenti F
Clin Pharmacol Ther; 2014 Dec; 96(6):655-7. PubMed ID: 25399714
[TBL] [Abstract][Full Text] [Related]
14. [The future of pharmacogenetics--cost-effectiveness and barriers].
Gyrd-Hansen D
Ugeskr Laeger; 2005 May; 167(20):2153-5. PubMed ID: 15987071
[No Abstract] [Full Text] [Related]
15. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.
Marra CA; Esdaile JM; Anis AH
J Rheumatol; 2002 Dec; 29(12):2507-12. PubMed ID: 12465143
[TBL] [Abstract][Full Text] [Related]
16. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing.
Deverka PA; McLeod HL
Clin Pharmacol Ther; 2008 Aug; 84(2):191-3. PubMed ID: 18679180
[TBL] [Abstract][Full Text] [Related]
17. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
Yeo SI
Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
[TBL] [Abstract][Full Text] [Related]
18. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics.
Lesko LJ
Clin Pharmacol Ther; 2008 Sep; 84(3):301-3. PubMed ID: 18714317
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of genotyping to guide treatment.
Sorich MJ; Wiese MD; Pekarsky B
Pharmacogenomics; 2014 Apr; 15(6):727-9. PubMed ID: 24897279
[No Abstract] [Full Text] [Related]
20. Pharmacogenetics in clinical practice: considerations for testing.
Constable S; Johnson MR; Pirmohamed M
Expert Rev Mol Diagn; 2006 Mar; 6(2):193-205. PubMed ID: 16512779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
